Black Rock Inc. Outlook Therapeutics, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.22 - $0.66 $214,031 - $642,095	972,872 Added 10.36%	10,366,285 $4.04 Million
Q3 2023 Nov 13, 2023	BUY	$0.2 - $1.78 $35,522 - $316,151	177,613 Added 1.93%	9,393,413 $2.07 Million
Q2 2023 Aug 11, 2023	BUY	$1.02 - $1.89 $1.17 Million - $2.17 Million	1,148,372 Added 14.23%	9,215,800 $16 Million
Q1 2023 May 12, 2023	BUY	$1.0 - $1.35 $1.02 Million - $1.38 Million	1,021,436 Added 14.5%	8,067,428 $8.79 Million
Q4 2022 Feb 13, 2023	BUY	$0.87 - $1.33 $164,862 - $252,031	189,497 Added 2.76%	7,045,992 $7.61 Million

Q3 2022 Nov 14, 2022	SELL	$1.02 - $1.26 $101,094 - $124,881	-99,112 Reduced 1.42%	6,856,495 $8.36 Million
Q2 2022 Aug 12, 2022	BUY	$0.91 - $2.01 $250,696 - $553,736	275,491 Added 4.12%	6,955,607 $7.09 Million
Q1 2022 May 12, 2022	BUY	$1.22 - $2.03 $928,854 - $1.55 Million	761,356 Added 12.86%	6,680,116 $11.9 Million
Q4 2021 Feb 10, 2022	BUY	$1.27 - $2.23 $101,787 - $178,730	80,148 Added 1.37%	5,918,760 $8.05 Million
Q3 2021 Nov 09, 2021	BUY	$2.12 - $2.76 $179,508 - $233,700	84,674 Added 1.47%	5,838,612 $12.7 Million
Q2 2021 Aug 11, 2021	BUY	$1.78 - $2.76 $10.2 Million - $15.9 Million	5,753,938 New	5,753,938 $14.3 Million

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.67B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.